Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/18/2026, 12:00:00 AM
The U.S. FDA approved Icotyde on March 18, 2026, a once-daily oral treatment for moderate-to-severe plaque psoriasis, which has a multi-billion dollar peak sales potential.
Korean Translation
2026년 3월 18일, 미국 FDA는 수십억 달러의 최고 매출 잠재력을 가진 중등도에서 중증의 판상 건선에 대한 1일 1회 경구 치료제인 이코타이드(Icotyde)를 승인함
Related Recent Events
Target Corp (TGT) · Earnings Release
Q1 2026 earnings release scheduled for 2026-05-20 scheduled.
5/20/2026, 12:00:00 AM
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Williams Cos Inc. (The) (WMB) · Earnings Release
Q1 2026 earnings release is scheduled for 2026-05-04. Earnings releases typically result in a price impact of at least 5%. Analysts forecast EPS of approximately $0.62-$0.63 forecasted.
5/4/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
First quarter 2026 earnings release and conference call scheduled for April 30, 2026; ≥1% price impact estimated upon release, scheduled.
4/30/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
Q1 2026 earnings release scheduled. Medium importance is assigned as earnings releases typically cause price volatility exceeding 5%.
4/28/2026, 12:00:00 AM